3.15 0.00 (0.00%)
After hours: 4:59PM EDT
|Bid||2.98 x 1000|
|Ask||3.30 x 2900|
|Day's Range||3.13 - 3.26|
|52 Week Range||2.78 - 7.00|
|Beta (3Y Monthly)||2.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / October 8, 2018 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York ...
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors (“Board”) of Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (NASDAQ CM: KERX) related to the Company’s entry into an agreement to merge with Akebia Therapeutics, Inc. (“Akebia”) (NASDAQ GM: AKBA) in a transaction announced on June 28, 2018 (the “Proposed Transaction”). On June 28, 2018, the Board caused Keryx to enter into an agreement and plan of merger (the “Merger Agreement”) with Akebia. Pursuant to the terms of the Merger Agreement, shareholders of Keryx will receive 0.37433 common shares of Akebia for each share of Keryx they own.
NEW YORK , Oct. 1, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City ...
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will participate in the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 in New York. At the conference, Keryx will be participating in a 25 minute panel discussion titled Renal Anemia on Tuesday, October 2, 2018 at 3:30 p.m. Eastern time at the Sofitel New York in New York City. A live audio webcast of both the panel discussion will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “events and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the panel discussion.
RADNOR, PA / ACCESSWIRE / September 10, 2018 / Kaskela Law LLC is investigating Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ: KERX) on behalf of the Company's stockholders. ...
Second quarter 2018 total revenues of $25.7 million, including net U.S. Auryxia ® product sales of $24.1 million; a 71 percent increase compared to the second quarter of 2017 Approximately 42,500 Auryxia ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:00 AM Eastern ...
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its second quarter 2018 financial results and provide a business update. Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease.
If you are looking to diversify your portfolio away from trade-war jitters and earnings volatility, consider the highly lucrative health care sector. Most of the sector's companies don't fall under the tariffs being threatened on all sides. Indeed, the health care sector - as measured by the Health Care Select Sector SPDR (XLV) - is the third best-performing sector so far in 2018, behind technology and consumer discretionary stocks. From a breadth perspective, health care trailed only technology as of mid-July, with 67% of its components posting gains since the start of the year. Another attractive feature is health care's "pop" potential - prices can surge on the back of positive clinical trial data or key regulatory approvals. However, prices can plunge just as quickly if data or decisions disappoint. That's why investing in the health care sector requires some savvy analysis first. TipRanks market data can help, as it allows you to tune into the experts' takes. Here are seven promising health care stocks to buy, according to Wall Street's pros. Each of these stocks has a "Buy" or "Strong Buy" analyst consensus rating and juicy upside potential, with analysts believing some could double or more. SEE ALSO: 25 Stocks Every Retiree Should Own
Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
NEW YORK , June 29, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" ...
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Shares of both companies tumble after the two entities announced the signing of a merger agreement. Here's what investors need to know.
The companies are to form a new, fully integrated company focused on chronic kidney diseases (or CKD) called Akebia Therapeutics. If Keryx Biopharmaceuticals manages to completely convert its outstanding convertible notes, the pro forma equity value of the combined company would be $1.3 billion, based on the closing share prices of the companies yesterday. Keryx is to add Auryxia, a drug approved by the FDA for hyperphosphatemia in CKD patients dependent on dialysis and for iron deficiency anemia in CKD patients not dependent on dialysis, to Akebia Therapeutics’ product portfolio.
Akebia Therapeutics, Inc. (AKBA) and Keryx Biopharmaceuticals, Inc. (KERX) today announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger agreement under which the companies will combine in an all-stock merger. The transaction will create a fully integrated biopharmaceutical company focused on chronic kidney disease (CKD), with an implied pro forma equity value of approximately $1.3 billion, assuming full conversion of Keryx’s outstanding convertible notes, based on the closing prices of Keryx and Akebia on June 27, 2018. The combined company will be named Akebia Therapeutics, Inc.